Pepcid AC and PPIs
This article was originally published in The Tan Sheet
Executive Summary
Study showing effectiveness of J&J/Merck's famotidine H2 antagonist brings end to NAD challenge by Pfizer/Warner-Lambert, CBBB division says in November Case Reports. Zantac 75 and Rolaids marketer objected to three ads calling Pepcid a "complement" to Rx proton pump inhibitors such as AstraZeneca's Prilosec. While noting firm should have substantiated claims before making them, NAD closes case
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning